163 related articles for article (PubMed ID: 31917332)
1. Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer.
Niemelä E; Desai D; Niemi R; Doroszko M; Özliseli E; Kemppainen K; Rahman NA; Sahlgren C; Törnquist K; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2020 Mar; 148():1-9. PubMed ID: 31917332
[TBL] [Abstract][Full Text] [Related]
2. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
Kalhori V; Magnusson M; Asghar MY; Pulli I; Törnquist K
Endocr Relat Cancer; 2016 May; 23(5):457-68. PubMed ID: 26935838
[TBL] [Abstract][Full Text] [Related]
3. A Carrier-Free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy.
Lan JS; Qin YH; Liu L; Zeng RF; Yang Y; Wang K; Ding Y; Zhang T; Ho RJY
Int J Nanomedicine; 2021; 16():1775-1787. PubMed ID: 33692622
[TBL] [Abstract][Full Text] [Related]
4. Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Li Y; Zhang H; Chen Y; Ma J; Lin J; Zhang Y; Fan Z; Su G; Xie L; Zhu X; Hou Z
Biomater Sci; 2018 Jun; 6(7):1818-1833. PubMed ID: 29785434
[TBL] [Abstract][Full Text] [Related]
5. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
6. Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer.
Zou X; Jiang Z; Li L; Huang Z
Artif Cells Nanomed Biotechnol; 2021 Dec; 49(1):83-95. PubMed ID: 33438446
[TBL] [Abstract][Full Text] [Related]
7. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
8. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
10. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract][Full Text] [Related]
11. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors.
Rosenholm JM; Peuhu E; Bate-Eya LT; Eriksson JE; Sahlgren C; Lindén M
Small; 2010 Jun; 6(11):1234-41. PubMed ID: 20486218
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
13. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells.
Sarkar A; Ghosh S; Chowdhury S; Pandey B; Sil PC
Biochim Biophys Acta; 2016 Oct; 1860(10):2065-75. PubMed ID: 27392941
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
15. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
[TBL] [Abstract][Full Text] [Related]
16. Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles.
Li S; Zhang D; Sheng S; Sun H
Int J Nanomedicine; 2017; 12():5993-6003. PubMed ID: 28860762
[TBL] [Abstract][Full Text] [Related]
17. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
18. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
Ke Y; Xiang C
Int J Nanomedicine; 2018; 13():8339-8354. PubMed ID: 30584304
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
20. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
